Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hydrocortisone + tofacitinib
- Development stage
- Preclinical
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral, Intravenous, Rectal
01
Overview
A combination of hydrocortisone, a glucocorticoid corticosteroid, and tofacitinib, a Janus kinase (JAK) inhibitor. Hydrocortisone acts by binding to the glucocorticoid receptor, inhibiting inflammatory pathways including phospholipase A2 and NF-kappa B. Tofacitinib works by inhibiting JAK1 and JAK3, preventing phosphorylation and activation of STATs, thereby decreasing T-cell activation and pro-inflammatory cytokine production. When used together, they may have synergistic immunosuppressive effects, potentially increasing efficacy in inflammatory conditions but also increasing the risk of infections, particularly herpes zoster.
02
Targets
Beyond the preview
Go deeper on hydrocortisone + tofacitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hydrocortisone + tofacitinib.